The company IVAO announces the completion of the projects to the scientists who conduct research in the field of life extension and longevity.
The company IVAO announces the completion of the projects to the scientists who conduct research in the field of life extension and longevity.
Expert against the aging of the company AI VAO
Professor of RAS, doctor of biological Sciences, head of laboratory of molecular radiobiology and gerontology Institute of biology Komi SC UB RAS, head of the Department of ecology, Syktyvkar state University, head of laboratory of genetics of longevity and aging in Moscow Physico-Technical Institute. The author of more than 60 publications the areas of genetics of aging, genetics, lifespan, radiation genetics. Researched the genome of Drosophila, including genes in life expectancy. Member of the editorial boards of several scientific journals: Biogerontology, Frontiers in Genetics of Aging, Aging.
Director of science of the company AI VAO
Andrew has over 10 years experience of research in Biomedicine. On the end graduate of Moscow state University, Andrew conducted research in the hospital of the University of Oslo, Norway. In currently the company is run by Digital BioPharm Ltd., specializing in preclinical the trials in the field of Oncology and diseases related to aging. In the project IVAO Andrew oversees the section "Science". He also conducts research and reads lectures in Moscow state University and MIPT. Andrew is the author of scientific publications in leading scientific magazines and a holder of 2 patents. A. Voronkov graduated from the chemical faculty and graduate school in Moscow State University.
Director of the company's investment AI VAO
Alexander has 7 years of experience in the financial industry, which includes market of shares, debt market, exchange-traded (ETD) and OTC derivatives (OTC). Before joining IVAO he worked with brokerage companies (including Broco Investments) and banks (including as the Northern Trust) to Russia and USA. The focus of his work was on alternative the investment (foreign exchange market, exchange-traded (ETD) and OTC derivatives (Credit Default Swaps, Interest Rate Swaps, Forwards). A. Novikov graduated from Keller Graduate School of Management (Chicago, Il).
MineGenics — diagnostic test for the early diagnosis and prevention vascular calcification
Contact information — http://minegenics.com
In currently, cardiovascular diseases (CVD) year year confidently occupy a leading position on the number of people it kills in developed developing countries. CVD can be caused by improper lifestyle, genetic predisposition and metabolic abnormalities of the patients. GCC shows the age, and already every second man older than 40 years are the first signs CVD most Often, the cardiovascular system loses its elasticity, and functionality which is caused by the accumulation of calcium salts and formation of structures resembling bone in soft the tissues of the vessels and heart patient. In patients with calcification in a few times higher risk of death from heart and in surgical operations on the heart.
In the risk of developing calcification is hundreds of millions of people around the world, among patients with atherosclerosis, diabetes, chronic renal failure and osteoporosis. For the last 20 years of research world the scientific community has recognized the serious calcification and widespread pathology cardiovascular system that needs to be treated. We are analyzed the data patients and literature, come to the conclusion that by calcification lead changes in a variety of molecular mechanisms. Moreover, calcification in late irreversible stages, and patients can only treat the symptoms. In connection the, we have developed a personalized approach to prevent the development of calcinosis.
Diagnostic test system provides information about the likelihood of calcinate and recommendations to prevent the development of calcification of CVD on the basis of the analysis selected RNA blood markers, genetic data and the results of biochemical tests patient. For through personalized approach and multi-factor analysis, we plan to increase the effectiveness of therapy and significantly reduce the likelihood of developing calcinosis in patients, who will benefit from our product.
The diagnostic system consists of a platform and panel of primers for the detection of RNA markers of calcification in the patient's blood. Diagnosis of the patient begins with the selection 1 ml of blood, preparation of material and analysis using the technology cat-PCR with the aim of determining the values of RNA markers in the patient. Then the doctor makes data markers of calcification, biochemical and genetic patient data in the web framework "MineGenics". Founded in the platform, the algorithm calculates the probability of development of calcinosis in the patient warns of the first signs of calcification and provides recommendations medicines and dietary Supplements for the prevention of calcification of cardiovascular system.
The diagnostic system consists of a platform and panel of primers for the detection of RNA markers of calcification in the patient's blood. Diagnosis of the patient begins with the selection 1 ml of blood, preparation of material and analysis using the technology cat-PCR with the aim of determining the values of RNA markers in the patient. Then the doctor makes data markers of calcification, biochemical and genetic patient data in the web framework "MineGenics". Founded in the platform, the algorithm calculates the probability of development of calcinosis in the patient warns of the first signs of calcification and provides recommendations medicines and dietary Supplements for the prevention of calcification of cardiovascular system.
Medical institutions and diagnostic centers. Direct sales and sales through distributors.
Patients:
the moment, the only way to get rid of calcification CCC remains surgery for the removal of the affected area and installing the endoprosthesis (if possible). Such surgical operations are carried out in $ 100 PCs. in month. On the external market also developing competitive diagnostic system in the company Calciscon, which allows to determine the susceptibility of the patient to calcification on the basis of the analysis of biochemical characteristics of plasma, blood the patient with using nephelometry with resolution time (atypical a device for therapeutic and diagnostic institutions, hinders the widespread dissemination method in clinical practice).
CEO LLC «MineGenics"
Specialist in the field of Molecular biology, 3 years experience of commercial promotion and non-profit projects, the finalist ’s Formula Bio’, Startup Village, the accelerator finalist Generation S 2015, master "Nanotechnology" people's friendship University.
Director of science, LLC «MineGenics", Moscow, Russia
Specialist in the field of molecular biology and bioinformatics, PhD student, faculty of of bioengineering and bioinformatics, Lomonosov Moscow state University. M. V. Lomonosov. Author of 6 scientific publications in the field of molecular biology and bioinformatics, the winner of the grant of the President of the Russian Federation, the winner of the award with the medal of RAS for young scientists and students, the winner scholarships MSU M. V. Lomonosov Moscow state University for talented young scientists and graduate students.
Director of science technology co., LTD «MineGenics"
Specialist in the field of medical biochemistry and bioinformatics, postgraduate student of the faculty of bioengineering and bioinformatics, Lomonosov Moscow state University. M. V. Lomonosov is the Author of 6 scientific publications in the field biochemistry and bioinformatics, winner of the scholarship MSU M. V. Lomonosov Moscow state University for talented young scientists and graduate students.
The project of the Stavropol State Medical University
Project Manager — albert Belatchew
The project — "Private company"
Project Manager — Alexander Antipov
The project — “a Private company of Westheimer Engelhorn"
Project Manager — Westheimer Engelhorn